JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

High Tumor Mutational Burden in Hepatocellular Carcinoma

  • 0Department of Medicine, Summa Health, Akron, USA.
Cureus +

|

September 30, 2024

|

September 30, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This case study examines an exceptionally high tumor mutational burden (TMB) in hepatocellular carcinoma (HCC). The aggressive nature of this high TMB highlights the need for further research into its prognostic and therapeutic implications in liver cancer.

Area Of Science

  • Oncology
  • Genetics
  • Cancer Research

Background

  • Hepatocellular carcinoma (HCC) is a prevalent and deadly liver cancer.
  • Tumor mutational burden (TMB) is an emerging biomarker for cancer prognosis and immunotherapy response.
  • The role of TMB in HCC is not well-defined due to typically low TMB values in this cancer type.

Observation

  • A 72-year-old female presented with advanced, diffuse HCC.
  • Genetic analysis revealed an exceptionally high TMB of 87 mutations per megabase, which is rare for HCC.
  • The patient experienced rapid disease progression despite treatment with immunotherapy.

Findings

  • This case presents an outlier HCC with a significantly elevated TMB.
  • The aggressive clinical course suggests a potential correlation between high TMB and poor prognosis in HCC.
  • The patient's rapid decline limited the assessment of immunotherapy efficacy.

Implications

  • Further research into high TMB in HCC is crucial for understanding its impact on prognosis.
  • Investigating TMB in outlier cases may refine patient stratification for immunotherapy.
  • Understanding TMB's role could improve clinical decision-making and treatment strategies for HCC.

Keywords:

Related Concept Videos

Adaptive Mechanisms in Cancer Cells 02:53

5.7K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Mutagenicity and Carcinogenicity 01:25

1.2K

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Cancers Originate from Somatic Mutations in a Single Cell 02:21

11.8K

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Cancer-Critical Genes II: Tumor Suppressor Genes 01:05

7.3K

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...